Cell therapy developers took the lion’s share of private equity and venture capital funds raised in China in October, with three firms bagging north of CNY300m ($41m) in total.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?